Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: A randomised, double-blind, placebo-controlled study

International Journal of Clinical Practice

Volumn 60, Issue 8, 2006, Pages 906-910

  Kuo, C S ^a,b,c   Pei, D ^b   Yao, C Y ^b   Hsieh, M C ^b   Kuo, Shi Wen ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Body mass index; Obesity; Orlistat; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE FUNCTION DISORDER; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BODY MASS INDEX; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; OBESITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746127561     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01052.x     Document Type: Article

References (37)

1. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 2001; 24: S44-7.
2. Kopelman PG, Albon L. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull 1997; 53: 322-40.
3. Wing R, Koeske R, Epstein L, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-53.
4. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66.
5. Hughes TA, Gwynne JT, Switzer BR, Herbst C, White G. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. JAMA 1984; 77: 7-17.
6. Kelly DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3: 366-7.
7. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-504.
8. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-6.
9. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylureas, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirements for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 21: 2005-12.
10. United Kingdom Prospective Diabetes Study (UKPDS) 13. Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8.
11. Zhi J, Melia A, Guerciolini R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-5.
12. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipases inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55 (Suppl. 1): 309S-13S.
13. Jebb SA. Aetiology of obesity. Br Med Bull 1997; 53: 264-85.
14. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. Davidson M, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized-controlled trial. JAMA 1999; 281: 235-42.
16. Sjöström L, Rissanen A, Andersen T et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73.
17. Priscilla AH, Roy AK, Steven CE et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-94.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
19. Chan JC, Cockram CS. Diabetes in the Chinese population and its implications for health care. Diabetes Care 1997; 20: 1785-90.
20. Chuang LM, Tsai ST, Huang BY, Tai TY. The current state of diabetes management in Taiwan. Diabetes Res Clin Pract 2001; 54 (Suppl. 1): S55-65.
21. Lin YC, Yen LL, Chen SY et al. Prevalence of overweight and obesity and its associated factors: Findings from National Nutrition and Health Survey in Taiwan, 1993-1996. Prev Med 2003; 37: 233-41.
22. Miles JM, Doyle M, Letter L et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8.
23. Meigs JB, Singer DE, Sullivan LM et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. Am J Med 1997; 102: 38-47.
24. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-94.
25. Stratton IM, Adler AI, Neil HAW et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-12.
26. Mittendorfer B, Ostlund R, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2000; 8 (Suppl. 1): S43-7.
27. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-8.
28. Lin T, Chou P, Lai MS, Tsai ST, Tai TY. Direct costs-of-illness of patients with diabetes mellitus in Taiwan. Diabetes Res Clin Pract 2001; 54 (Suppl. 1): S43-6.
29. Colditz GA, Wilett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-6.
30. Must A, Spadano J, Caokley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9.
31. Hu FB, Manson JE, Stampfer MJ et al. Diet, life style, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-9.
32. Kumayika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: The case for action. Int J Obes Relat Metab Disord 2002; 26: 425-36.
33. Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-5.
34. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
35. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
36. Heymsfield SB, Segal KR, Hauptman J et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6.
37. Torgerson JS, Boldrin MN, Hauptman J, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study - a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.